[go: up one dir, main page]

WO2009140621A3 - Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof - Google Patents

Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof Download PDF

Info

Publication number
WO2009140621A3
WO2009140621A3 PCT/US2009/044186 US2009044186W WO2009140621A3 WO 2009140621 A3 WO2009140621 A3 WO 2009140621A3 US 2009044186 W US2009044186 W US 2009044186W WO 2009140621 A3 WO2009140621 A3 WO 2009140621A3
Authority
WO
WIPO (PCT)
Prior art keywords
targets
compositions
transcription factor
heat shock
activating compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/044186
Other languages
French (fr)
Other versions
WO2009140621A8 (en
WO2009140621A2 (en
Inventor
Dennis J. Thiele
Daniel W. Neef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Priority to CN2009801261985A priority Critical patent/CN102088973A/en
Priority to CA2724413A priority patent/CA2724413C/en
Priority to EP09747702A priority patent/EP2300004A4/en
Publication of WO2009140621A2 publication Critical patent/WO2009140621A2/en
Publication of WO2009140621A3 publication Critical patent/WO2009140621A3/en
Priority to US12/945,522 priority patent/US9315449B2/en
Anticipated expiration legal-status Critical
Publication of WO2009140621A8 publication Critical patent/WO2009140621A8/en
Priority to US15/131,938 priority patent/US9718784B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses. In particular, the present invention provides compounds capable of facilitating HSFl activation, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with protein misfolding.
PCT/US2009/044186 2008-05-15 2009-05-15 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof Ceased WO2009140621A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN2009801261985A CN102088973A (en) 2008-05-15 2009-05-15 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
CA2724413A CA2724413C (en) 2008-05-15 2009-05-15 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
EP09747702A EP2300004A4 (en) 2008-05-15 2009-05-15 COMPOSITIONS AND METHODS RELATING TO THERMAL SHOCK TRANSCRIPTION FACTOR-ACTIVE COMPOUNDS AND CORRESPONDING TARGETS
US12/945,522 US9315449B2 (en) 2008-05-15 2010-11-12 Substituted pyrazoles as heat shock transcription factor activators
US15/131,938 US9718784B2 (en) 2008-05-15 2016-04-18 Substituted pyrazoles as heat shock transcription factor activators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5351308P 2008-05-15 2008-05-15
US61/053,513 2008-05-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/945,522 Continuation-In-Part US9315449B2 (en) 2008-05-15 2010-11-12 Substituted pyrazoles as heat shock transcription factor activators

Publications (3)

Publication Number Publication Date
WO2009140621A2 WO2009140621A2 (en) 2009-11-19
WO2009140621A3 true WO2009140621A3 (en) 2010-02-25
WO2009140621A8 WO2009140621A8 (en) 2011-05-12

Family

ID=41319361

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/044186 Ceased WO2009140621A2 (en) 2008-05-15 2009-05-15 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof

Country Status (4)

Country Link
EP (1) EP2300004A4 (en)
CN (1) CN102088973A (en)
CA (1) CA2724413C (en)
WO (1) WO2009140621A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
CA2793311C (en) 2010-03-17 2019-01-15 Taivex Therapeutics Inc. Modulators of hec1 activity and methods therefor
RU2639876C2 (en) 2010-03-30 2017-12-25 Версеон Корпорейшн Multi-substituted aromatic compounds as thrombin inhibitors
MX375276B (en) 2011-11-21 2025-03-06 Taivex Therapeutics Corp BIOMARKERS FOR CANCERS THAT RESPOND TO MODULATORS OF HEC1 ACTIVITY.
US11071736B2 (en) 2011-11-21 2021-07-27 Taivex Therapeutics Corporation Modulators of HEC1 activity and methods therefor
NZ711064A (en) 2013-03-15 2019-06-28 Verseon Corp Pyridone-substituted pyrazolyl compounds as serine protease inhibitors
HK1214252A1 (en) 2013-03-15 2016-07-22 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
AU2016224974B2 (en) 2015-02-27 2019-09-26 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
US11028061B2 (en) * 2015-07-27 2021-06-08 Sanford Burnham Prebys Medical Discovery Institute Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof
CN105524056A (en) * 2016-01-05 2016-04-27 中山大学肿瘤防治中心 Aminothiazole compound, and preparation method and application thereof
CN107519239A (en) * 2017-04-25 2017-12-29 兰州大学 Baical Skullcap root P.E is preparing the application in activating HSP70 medicines
WO2019241376A1 (en) 2018-06-14 2019-12-19 The Trustees Of Columbia University In The City Of New York Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
CN112969687B (en) 2018-10-30 2024-08-23 吉利德科学公司 Quinoline derivatives as a4 b 7 integrin inhibitors
CA3115820A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
EP3873900B1 (en) 2018-10-30 2025-01-08 Gilead Sciences, Inc. Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
WO2020157652A2 (en) 2019-01-31 2020-08-06 Pfizer Inc. Cdk2 inhibitors
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin
CN113087783B (en) * 2021-04-20 2021-10-01 南京医科大学 Small Molecular Polypeptides in HD Therapeutic Drugs and Their Applications

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000300A1 (en) * 2003-06-27 2005-01-06 Vernalis (Cambridge) Limited Substituted 5-membered ring compounds and their use
WO2005041879A2 (en) * 2003-10-28 2005-05-12 Pharmacia Corporation COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
WO2005044194A2 (en) * 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
WO2007120343A2 (en) * 2005-12-19 2007-10-25 New York University Heat shock rna and its use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2525547C (en) * 2003-05-14 2012-07-03 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
CA2537841A1 (en) * 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
KR100874315B1 (en) * 2004-08-05 2008-12-18 에프. 호프만-라 로슈 아게 Substituted n-acyl-2-aminothiazoles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000300A1 (en) * 2003-06-27 2005-01-06 Vernalis (Cambridge) Limited Substituted 5-membered ring compounds and their use
WO2005041879A2 (en) * 2003-10-28 2005-05-12 Pharmacia Corporation COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
WO2005044194A2 (en) * 2003-10-28 2005-05-19 Pharmacia Corporation TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
WO2007120343A2 (en) * 2005-12-19 2007-10-25 New York University Heat shock rna and its use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LAKSHMI GALAM ET AL.: "High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase.", BIOORGANIC & MEDICINAL CHEMISTRY., vol. 15, no. 5, 2007, pages 1939 - 1946, XP005867161 *
See also references of EP2300004A4 *

Also Published As

Publication number Publication date
EP2300004A2 (en) 2011-03-30
CA2724413A1 (en) 2009-11-19
CN102088973A (en) 2011-06-08
WO2009140621A8 (en) 2011-05-12
EP2300004A4 (en) 2012-05-30
WO2009140621A2 (en) 2009-11-19
CA2724413C (en) 2016-10-18

Similar Documents

Publication Publication Date Title
WO2009140621A8 (en) Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
WO2007095638A3 (en) Boron-containing small molecules as anti-inflammatory agents
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
WO2009111676A8 (en) Boron-containing small molecules as anti-inflammatory agents
EP4406950A3 (en) Lfa-1 inhibitor and polymorph thereof
WO2008028117A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses
CL2007003765A1 (en) COMPOUNDS DERIVED FROM 2-OXO-4-HIDROXI-BENZOTIAZOL; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMBINATION; AND USE IN THE TREATMENT OF DISEASES SUCH AS COPD, BRONCHITIS, ASTHMA AND BRONCHIECTASIES.
WO2009089537A3 (en) Anti-cancer compounds
WO2010003533A3 (en) Pyridopyrimidine compounds as anti-tubercular agents
EP3000885A3 (en) Organic compositions to treat hsf1-related diseases
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2009023509A3 (en) Therapeutic combinations useful in treating cftr related diseases
WO2011083150A3 (en) Obesity small molecules
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2009108730A3 (en) Forms of rifaximin and uses thereof
WO2010038086A3 (en) P38 map kinase inhibitors
EP4435100A3 (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
WO2008089397A3 (en) Adrb2 cancer markers
WO2010030983A3 (en) Pyrazole carboxamide inhibitors of factor xa
WO2008042686A3 (en) Multifunctional carriers for the delivery of nucleic acids and methods of use thereof
WO2010032011A3 (en) Anti-fungal therapy
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
WO2007067828A3 (en) Glp-2 mimetibodies, polypeptides, compositions, methods and uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980126198.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2724413

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 8508/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009747702

Country of ref document: EP